Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCare PharmaINCPF 83 Gross Margin % is 93.04% as of Dec. 2025, which is 8% above its 10-year median of 86.29. GuruFocus rates INCPF with a GF Score™ of 83/100 and a GF Value™ of $2.32. The stock has 7 warning signs investors should review. Among 735 Biotechnology companies, InnoCare Pharma ranks better than 86.67% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
InnoCare Pharma had a gross margin of 93.04% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
InnoCare Pharma Gross Margin % Related Terms
InnoCare Pharma Gross Margin % Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INCPF vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, InnoCare Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Gross Margin % distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
InnoCare Pharma (INCPF) has a Gross Margin % of 93.04% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on InnoCare Pharma and its competitors. This is near median its historical median of 86.29. Over the past decade, InnoCare Pharma's Gross Margin % has ranged from 77.07 to 93.70. According to the industry distribution chart, InnoCare Pharma ranks #98 out of 735 companies in the Biotechnology industry, placing it in the top 13.3%.
Is InnoCare Pharma's Gross Margin % too high?
InnoCare Pharma's current Gross Margin % of 93.04% is near median its 10-year median of 86.29. Over the past 10 years, this metric has ranged from a low of 77.07 to a high of 93.70. The Biotechnology industry median Gross Margin % is 60.96. InnoCare Pharma's value of 93.04% is 52.6% above this industry median. Based on the distribution chart, InnoCare Pharma ranks #98 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #98 out of 735 companies for Gross Margin %. This places InnoCare Pharma in the top 13% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.96. InnoCare Pharma's value of 93.04% is 52.6% above this benchmark. Historically, InnoCare Pharma's own Gross Margin % has ranged from 77.07 to 93.70 over the past decade. While the company's 10-year median is 86.29 vs. the industry median of 60.96, InnoCare Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.96, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Pharma's current Gross Margin % of 93.04% is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on InnoCare Pharma and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current Gross Margin % is 93.04%, which is near median its own 10-year median of 86.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current Gross Margin % of 93.04%. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current Gross Margin % is 93.04%, which is near median its 10-year median of 86.29 and 52.6% above the Biotechnology industry median of 60.96. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current Gross Margin % is 93.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (INCPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.
Key valuation signals for INCPF:
Gross Margin %: 93.04% (near median its 10-year median of 86.29)
GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
Industry Position: 52.6% above the Biotechnology median (#98 of 735)
No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for INCPF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCPF has been successfully added to your 
